

# LUND UNIVERSITY

## Exosomal microRNAs as Potential Biomarkers in Castration-resistant Prostate Cancer.

Haflidadottir, Benedikta; Ceder, Yvonne

Published in: European Urology

DOI: 10.1016/j.eururo.2014.08.067

2015

#### Link to publication

Citation for published version (APA): Haflidadottir, B., & Ceder, Y. (2015). Exosomal microRNAs as Potential Biomarkers in Castration-resistant Prostate Cancer. European Urology, 67(1), 42-43. https://doi.org/10.1016/j.eururo.2014.08.067

Total number of authors: 2

#### General rights

Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

· Users may download and print one copy of any publication from the public portal for the purpose of private study

or research.
You may not further distribute the material or use it for any profit-making activity or commercial gain

· You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

#### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

#### LUND UNIVERSITY

**PO Box 117** 221 00 Lund +46 46-222 00 00

# 1 Exosomal microRNAs as potential biomarkers in Castration Resistant

# 2 **Prostate Cancer.**

- 3 Benedikta S. Haflidadóttir<sup>1</sup> and Yvonne Ceder<sup>2</sup>.
- <sup>1</sup>Institute of Biosciences and Medical Technology, University of Tampere and Tampere University
  Hospital, Tampere, Finland.
- <sup>6</sup> <sup>2</sup>Department of Laboratory Medicine, Lund, Division of Translational Cancer Research, Lund
- 7 University, Lund, Sweden.

### 8

- 9 **3-5 keywords:** microRNA, exosome, CRPC, biomarker
- 10 Word count: 988
- 11 Corresponding author:
- 12 Dr. Yvonne Ceder
- 13 Department of Laboratory Medicine, Lund,
- 14 Division of Translational Cancer Research,
- 15 Medicon Village, Building 404:A3
- 16 223 81 Lund, Sweden
- 17 Email: Yvonne.Ceder@med.lu.se
- 18 Phone: +46 46 2226452
- 19 Refers to: Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic
- 20 markers in castration-resistant prostate cancer. European Urology (in press).

Castration-resistant prostate cancer (CRPC) develops as metastatic prostate cancer patients 21 22 inevitably progress and become resistant to treatment targeting the androgen signalling axis; it represents the final stage of the disease with a median survival of less than two years. Although 23 CRPC remains incurable, a number of treatment alternatives that gives modest prolongation of life 24 have been developed and FDA approved during the last few years, e.g. selective adrenal inhibitors, 25 androgen receptor signalling inhibitors, novel immune compounds, and less toxic radio nucleotides. 26 27 The progression towards more personalised treatment strategies is however hampered by the lack of easily implemented reliable biomarkers predicting response to therapy and survival. In this month's 28 issue of European Urology, Huang et al., attempts to address this issue [1]. They have investigated 29 30 the prognostic potential of microRNAs (miRNAs) within exosomes in circulation and propose that two miRNAs, miR-375 and miR-1290, can serve as a prognostic biomarker in CRPC. 31

32

The miRNAs identified here are derived from exosomes in the blood circulation; extensive attention 33 34 is now being paid to these vesicles as a source of biomarkers as their content resembles that of the cell of origin. In 2008, Skog et al. showed the miRNA content of extracellular vesicles to be 35 reflective of the miRNA expression profile of the cells they originate from [5], however, it should 36 37 be noted that the miRNA content of the exosomes is not an uncorrupted sampling of the contents in the parental cells. When investigating the content of the plasma derived exosomes (or extracellular 38 vesicle) Huang et al. found mature miRNAs to be the most common RNA species [1]. This is in 39 40 agreement with earlier sequencing of the RNA content in prostatic tissues that also identified miRNA as the most abundant class, constituting 95% of the RNA pool [2]. The miRNAs are not 41 42 only the most abundant, but also technically suitable as biomarkers, as they can be easily and sensitively detected in small samples sizes by qRT-PCR and are stable in serum and plasma and 43 resistant to extended storage, freeze-thawing and extreme pH [3]. Over the last decade, miRNAs 44 have been found to be deregulated in prostate cancer and emerged as key players in cancer 45

progression and many studies highlight their diagnostic and prognostic potential [4]. Nevertheless, 46 47 the current study does not confirm that it is the expression of the individual miRNAs that are changed; it could also be the exosomal content in circulation or the RNA content of the exosomes. 48 As this also would be of great interest, it would have been informative to combine the evaluation of 49 individual miRNAs with an evaluation of the amount of extracellular vesicles and their RNA 50 content. The choice of reference genes is as important as the target genes in these studies, in the 51 52 discussed study 192 plasma samples are investigated to identify the endogenous reference control including men, women, healthy and other types of cancer as well as 23 cases in the screening 53 cohort. One of the reference genes, miR-30e, have been reported to be highly expressed in blood 54 55 cells, particularly in monocytes [6] this could indicate that a difference in exosomal content is 56 emphasised.

57

The first report of miRNAs as potential non-invasive diagnostic markers in a prostate cancer setting 58 came in 2008. Mitchell et al. compared a panel of miRNAs in serum from healthy men to men with 59 advanced prostate cancer and found that miR-141 was elevated in the cancer samples [7]. Giving 60 the heterogeneity of prostate cancer it is not surprising that although many miRNAs have since been 61 62 implicated as diagnostic and prognostic makers, no single miRNA has been consistently validated or implemented as a biomarker in clinical management of prostate cancer. In line with this, Huang 63 64 et al. show that the combination of miR-375 and miR-1290 gives increased significance in 65 prediction of survival compared to individually. The patients with high levels of both miR-375 and miR-1290 have significantly higher mortality rate than the patients with low levels of the two 66 miRNAs at the 20 month follow up. There is also a significant difference in the median overall 67 68 survival of patients with high levels of miR-375/1290 compared to the patients with low levels. Incorporation of miR-1290/-375 into a clinical prognostic factors-based model based on PSA and 69 ADT failure time, also significantly improved the predictive performance. It would have been very 70

interesting to have a comparison to CellSearch for the exosomal miRNAs as CellSearch is currently the only FDA approved prognostic biomarker for CRPC. If would also make it easier to compare with other similar studies *e.g.* a recent study by Danila *al*. that found a 5-gene panel measured in blood samples from 97 metastatic CRPC patients to be prognostic predictor for survival, comparable with the CellSearch system. Further, if combining the gene panel and CellSearch the prognostic powers were enhanced compared to CellSearch alone [8].

77

It is evident that CRPC is a heterogeneous disease and given the complexity of the AR signalling 78 cascade, the idea of a more complex panel of marker is appealing. Investigation if the inclusion of 79 several miRNAs would give more representative information on the patient status and how much 80 this could be improved is possible in the Huang et al. data set as the data of 375 known miRNAs 81 82 and 57 putative miRNAs is available. For example, one of the predicted miRNAs on chromosome 83 12 seems to have excellent potential. It is however encouraging that one of the miRNAs identified 84 in this paper, miR-375, has been described previously in several independent studies to be elevated 85 in metastatic CRPC serum as the authors discusses. Two cohorts are used in this study, a screening cohort of 23 individuals and a validation cohort constituting 100 men. Hopefully, there will be 86 future validation of presented biomarkers in larger independent cohorts to establish their reliability 87 and potential clinical applicability. To conclude, the current paper by Huang et al. reinforce the 88 notion that novel non-invasive prognostic methods for patients with CRPC will soon be a reality. 89

90

## 91 **References**

- [1] Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in
   castration-resistant prostate cancer. European Urology (in press).
- [2] Martens-Uzunova ES, Jalava SE, Dits NF, al. Diagnostic and prognostic signatures from the
   small non-coding RNA transcriptome in prostate cancer. Oncogene 2012; 31: 978–991.

- [3] Sita-Lumsden A, Dart DA, Waxman J, and Bevan CL. Circulating microRNAs as potential new
  biomarkers for prostate cancer. Br. J. Cancer 2013; 108:1925–1930.
- [4] Fang Y-X, and Gao W-Q. Roles of microRNAs during prostatic tumorigenesis and tumor
   progression. Oncogene 2014: 33: 135–147.
- [5] Skog J, Würdinger T, van Rijn, S, et al. Glioblastoma microvesicles transport RNA and proteins
  that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008; 10: 1470–
  1476.
- [6] Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: A cautionary
   note for cancer biomarker studies. Cancer Prev. Res. 2012; 5: 492–497.
- [7] Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers
  for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008; 105: 10513–10518.
- [8] Danila DC, Anand A, Schultz N et al. Analytic and clinical validation of a prostate cancerenhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.
  Eur. Urol. 2014; 65: 1191–1197.
- 110
- 111
  112
  113
  114
  115
  116
  117
  118
  119
- 120 **Conflict of interest**: The authors have nothing to disclose.